Pressure BioSciences, Inc. (PBIO)


Other OTC - Other OTC Delayed Price. Currency in USD
0.41-0.01 (-2.38%)
At close: 3:58 PM EDT
People also watch:
PDEXICCCPARDORXEPGLA
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open0.40
Prev Close0.42
Bid0.00 x
Ask0.00 x
Day's Range0.40 - 0.41
52wk Range0.20 - 0.58
1y Target EstN/A
Market Cap11.9M
P/E Ratio (ttm)-0.99
Beta0.77
Volume22,190
Avg Vol (3m)51,341
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Accesswire11 days ago

    WallStreet Research(TM) Announces Availability of Updated Corporate Profile Coverage on Pressure BioSciences, Inc. (OTCQB: PBIO)

    NEW YORK, NY / ACCESSWIRE / August 18, 2016 / WallStreet Research™, a top-ranked independent research firm with a history spanning over three decades, today announced that the firm has updated corporate ...

  • Zacks Small Cap Research12 days ago

    PBIO: Revenue Continues to Grow Nicely for Second Quarter 2016

    Total revenue for 2Q16 was $0.51 million, as compared to $0.41 million during the three months ended June, 2015, an increase of 24%. Two major drivers of product revenue growth were instrument sales, which increased 43% during the comparative quarterly periods (from $217,138 to $311,345) and consumable sales, which increased 29% (from $56,513 to a record $72,773). This decrease in grant revenue, which is expected to be short-term, allowed the Company to focus grant personnel in other critical areas during the second quarter of 2016, primarily in the development of the Barocycler 2320EXTREME, the company’s next-generation instrument system, and in various sales & marketing activities. The additional efforts in sales/marketing were partially responsible for the 24% increase reported in quarterly total revenue, from $413,104 in Q2 2015 to $510,963 in Q2 2016, despite the short-term decrease in grant revenue.